Evidence map›Paper›PMID 37460931›Full record

ArticleBMC complementary medicine and therapies2023

Shenkang protects renal function in diabetic rats by preserving nephrin expression.

Zhihui Qu, Biyao Wang, Yingli Jin, Qingfei Xiao, Ying Zhao, Danning Zhao, Liming Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC complementary medicine and therapies, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Zhihui QuDepartment of Nephrology, The First Hospital of Jilin University, No.3302, Jilin Road, Changchun City, Jilin Province, P.R. China.
Biyao WangDepartment of Clinical, Educational and Health Psychology, University College London, 26 Bedford Way, London, WC1H 0AP, UK.
Yingli JinDepartment of Pharmacology, College of Basic Medical Science, Jilin University, Changchun, 130021, P.R. China.
Qingfei XiaoDepartment of Nephrology, The First Hospital of Jilin University, No.3302, Jilin Road, Changchun City, Jilin Province, P.R. China.
Ying ZhaoDepartment of Nephrology, The First Hospital of Jilin University, No.3302, Jilin Road, Changchun City, Jilin Province, P.R. China.
Danning ZhaoDepartment of Medical Informatics, School of Public Health, Jilin University, Changchun, 130021, P.R. China.
Liming YangDepartment of Nephrology, The First Hospital of Jilin University, No.3302, Jilin Road, Changchun City, Jilin Province, P.R. China. lzyang@jlu.edu.cn.
Jilin University · CNJilin Medical University · CNUniversity College London · GB

Funding

the Basic Research Project of "Relationship between P27 and nephrin in the diabetic rats" from Jilin University, the International Cooperation Project No. 20160414026GHthe Development Plan Project from the Science and Technology Department of Jilin Province No. 20190201086JCthe Scientific Research Program of 13th Five Year Plan from the Education Department of Jilin Province No. JJKH20180242KJTransverse Project "Protective effect of ShenKang injection on renal function in diabetic nephropathy rats" No. 3R2139653428
6 · The paper itself

Abstract

backgroundShenkang injection has been used clinically to lower creatinine levels. This study explored the mechanism of Shenkang injection on protecting kidney function from hyperglycemia-mediated damage.

methodsThis study utilized a STreptoZotocin (STZ)-induced rat model of diabetes. In total, 60 rats were randomized into either the control group (n = 15) injected with vehicle or treatment group (n = 45) injected with STZ to induce hyperglycemia. Eight weeks after diabetes onset, diabetic rats were further randomized to receive different treatments for 4 consecutive weeks, including vehicle (diabetic nephropathy group, n = 15), Shenkang (n = 15), or Valsartan (n = 15). At 12 weeks, a series of urine and blood measures were examined and damage to the kidney tissue was examined using histology. Expression of nephrin and transforming growth factor-β1 (TGF-β1) were characterized using immunohistochemistry and Western blot.

resultsCompared to the control group, rats in the diabetic nephropathy group showed significant kidney damage demonstrated by high kidneyindex, high levels of urinary albumin, albumin/creatinine ratio (ACR), blood urea nitrogen as well as histological evidence. Shenkang injection significantly improved kidney function in the diabetic rats by decreasing kidney index, ACR, and serum creatinine. Shenkang treatment also mitigated kidney damage, improved nephrin expression, and decreased TGF-β1 expression in the kidneys.

conclusionsShenkang treatment protected renal function in diabetic rats by increasing nephrin expression, which protects diabetic rats from hyperglycemia-mediated kidney damage.

Indexed as

Diabetes Mellitus, ExperimentalDiabetic NephropathiesHyperglycemiaAlbuminsAnimalsCreatinineDrugs, Chinese HerbalKidneyMembrane ProteinsRatsTransforming Growth Factor beta1AlbuminsCreatinineDrugs, Chinese HerbalMembrane ProteinsnephrinshenkangTransforming Growth Factor beta1Albumin to creatinine ratioDiabetic nephropathyNephrinShenkang injectionTGF-β1

Identifiers

PMID37460931
PMCPMC10353195
OpenAlexW4384523549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.